Harmony Biosciences, LLC   Report issue

For profit Phase 4
Founded: Plymouth Meeting PA United States (2017)
Status: No NME R&D (2017)

Organization Overview

First Clinical Trial
2020
NCT04257929
First Marketed Drug
2019
pitolisant (Wakix)
First NDA Approval
None
Last Known Activity
2022

Timeline

NOW
  • Now

Alternative names

HARMONY | Harmony Biosciences, LLC

Active Ingredients

Marketed Drugs (1)

pitolisant (Wakix) (2019)

Drugs in Phase 4 Trials (1)

pitolisant (Wakix) (6 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Prader-Willi Syndrome (Phase 2)

Syndrome (Phase 2)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 6
  • # of Trial APIs: 1